Study SAKK 19/17 - Durvalumab in patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC) and inadequate general condition - A multicenter single-arm phase II study.
Summary of the study
This study is investigating how immunotherapy with durvalumab works and how well it is tolerated in patients with PD-L1-positive advanced NSCLC and an inadequate general condition. In addition, additional examinations of the tumor material and the blood will be used to better understand the effect of the immunotherapy and to find out why the therapy works better in some patients than in others. Durvalumab is an anti-PD-L1 antibody that has an effect on the immune system. The antibody recognizes PD-L1, a protein that is found on the surface of tumour cells in some patients. The tumor uses PD-L1 to hinder certain immune cells (T cells) in their task of destroying the tumor. By binding to PD-L1, durvalumab blocks its effect and can thus help your immune system to play an active role in tumor defense. This study is being conducted at several hospitals in Switzerland. 48 patients will be included in the study. All study participants will receive the same treatment (study drug Durvalumab). The study will last approximately 7.5 years. Durvalumab is not yet approved as a drug in Switzerland.
(BASEC)